0001493152-22-023376.txt : 20220817
0001493152-22-023376.hdr.sgml : 20220817
20220817201712
ACCESSION NUMBER: 0001493152-22-023376
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220815
FILED AS OF DATE: 20220817
DATE AS OF CHANGE: 20220817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carter Jennifer L.
CENTRAL INDEX KEY: 0001806505
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 221176034
MAIL ADDRESS:
STREET 1: C/O DFP SPONSOR LLC
STREET 2: 780 THIRD AVENUE, 37TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncocyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-409-7600
MAIL ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20200213
FORMER COMPANY:
FORMER CONFORMED NAME: Oncocyte Corp
DATE OF NAME CHANGE: 20200205
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20150513
4
1
ownership.xml
X0306
4
2022-08-15
0
0001642380
Oncocyte Corp
OCX
0001806505
Carter Jennifer L.
C/O ONCOCYTE CORPORATION
15 CUSHING
IRVINE
CA
92618
1
0
0
0
Common Stock, no par value
2022-08-15
4
A
0
10000
0
A
20000
D
Common Stock, no par value
2022-08-16
4
P
0
10500
0.95
A
30500
D
Option to Purchase Common Stock
0.97
2022-08-15
4
A
0
45000
0
A
2032-08-15
Common Stock
45000
45000
D
The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
/s/ Jennifer Levin Carter
2022-08-17